The legal entity is Caristo Diagnostics Limited, a spin-out company from the University of Oxford, incorporated in June 2018. Caristo was formed in order to build and commercialise novel cardiovascular disease assessment and diagnostics technologies developed within the OXACCT / Antoniades lab at the University. The first product, CaRi- Heart, analyses CT images of the heart to generate information on the inflammatory state of the arteries and hence predict risk of future cardiac events. This software, which will receive FDA clearance and CE-marking in 2020, is underpinned by CaRi-Cloud – an online platform for the secure transfer of medical data (particularly imaging) and delivery of cloud processing to apply AI algorithms to that data. The next product, CaRi-STROKE is in development under the BHF Translational Award won by Profs Antoniades and Casadei at Oxford.
